Multiple Myeloma Coverage from Every Angle

Larry D. Anderson, Jr, MD, PhD, on Idecabtagene Vicleucel CAR T-Cell Therapy in Multiple Myeloma

Posted: Monday, June 21, 2021

Larry D. Anderson, Jr, MD, PhD, of The University of Texas Southwestern Medical Center, discusses updated results from the KarMMa study, which continues to demonstrate deep, durable responses with idecabtagene vicleucel in heavily pretreated patients with relapsed and/or refractory multiple myeloma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.